Johnson & Johnson to develop a coronavirus vaccine

Johnson & Johnson (J&J) have recently commenced work on a coronavirus vaccine, in response to the hundreds of deaths and thousands of confirmed cases. However, J&J believes that the vaccine will take up to twelve months to develop and test on humans.

J&J will use the same PER.C6 and Advac technologies for the vaccine, previously used in their Ebola vaccine, to upscale manufacturing of the finest candidate.

J&J’s Chief Scientific Officer and Vice Chairman of the Executive Committee, Paul Stoffels, stated: “J&J has a long-standing commitment to fight established and emerging epidemics and is supporting global efforts where we can make the greatest impact. We are collaborating with regulators, healthcare organizations, institutions and communities worldwide to help ensure our research platforms, existing science and outbreak expertise can be maximised, to stem this public health threat. This latest outbreak of a novel pathogen once again reinforces the importance of investing in preparedness, surveillance and response to ensure the world remains ahead of potential pandemic threats.”